PCSK9 monoclonal antibodies: An overview

PCSK9 monoclonal antibodies: An overview

PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma lev...

Full description

Bibliographic Details
Main Authors: Rasha Kaddoura, Bassant Orabi, Amar M Salam
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Heart Views
Subjects:
alirocumab
antidrug antibody
bococizumab
cardiovascular diseases
evolocumab
familial hypercholesterolemia
neurocognitive
proprotein convertase subtilisin-kexin type 9 inhibitors
Online Access:http://www.heartviews.org/article.asp?issn=1995-705X;year=2020;volume=21;issue=2;spage=97;epage=103;aulast=Kaddoura

Internet

http://www.heartviews.org/article.asp?issn=1995-705X;year=2020;volume=21;issue=2;spage=97;epage=103;aulast=Kaddoura

Similar Items